Kimberly Maersk-Moller - 04 Mar 2026 Form 4 Insider Report for MIMEDX GROUP, INC. (MDXG)

Reporting relationship: Chief Commercial Officer
Issuer ticker: MDXG
Reported as of: 04 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Mar 2026, 17:42:25 UTC
Prior SEC filing: 10 Nov 2025
Next SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ William F. Hulse, as attorney-in-fact for Kimberly Maersk-Moller

Key filing fact

Kimberly Maersk-Moller filed Form 4 for MIMEDX GROUP, INC. (MDXG) on 06 Mar 2026.

Key facts

This page summarizes Kimberly Maersk-Moller's Form 4 filing for MIMEDX GROUP, INC. (MDXG).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Mar 2026, 17:42.

Change

Previous filing in this sequence was filed on 10 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002029167 Primary reporting owner

Maersk-Moller Kimberly

Relationship: Chief Commercial Officer
Address: 1775 WEST OAK COMMONS COURT, MARIETTA
Signature: /s/ William F. Hulse, as attorney-in-fact for Kimberly Maersk-Moller
Signature date: 06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDXG transaction

Common Stock

Award

Transaction value
Shares: +74,163
Change %: +31%
Price: $0.000000^*
Shares after: 314,637
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDXG transaction Derivative

Stock Options

Award

Transaction value
Shares: +62,068
Change %: +82%
Price: $0.000000^*
Shares after: 137,862
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,068
Exercise price: $5.10
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents grant of restricted stock which vests fully on the third anniversary of the grant, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement.

Footnote F2

Includes 3,492 shares acquired on January 30, 2026 pursuant to the MiMedx Group, Inc. Employee Stock Purchase Plan.

Footnote F3

The options granted to the reporting person shall vest 25% on each anniversary of the grant date, subject to the reporting person's continued employment as specified in the Nonqualified Stock Option Agreement.